Effects of Liraglutide on Myocardial Function After Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial
, Maarten J. Visscher 1,†, Thomas G. V. Cherpanath 4, Lieke van de Wouw 1, Marc B. Godfried 2, Bram Thiel 2, Bastiaan M. Gerritse 3, Thierry V. Scohy 3, R. Arthur Bouwman 5, Mark G. A. Willemsen 5, Markus W. Hollmann 1, J. Hans DeVries 6, Benedikt Preckel 1,* and Jeroen Hermanides 1
Round 1
Reviewer 1 Report
The authors present a subanalysis of a randomized blinded multicenter study aimed to assess the effect of a recently approved antidiabentic drug [Glucagon-like peptide-1 receptor agonists (GLP-1RA)] on the hemodinamic following cardiac surgery. In this study, GLP-1RA was applied on patients without Diabetes or with Diabetes mellitus Typ 2 needing a low Dosis of Insulin. Postoperatively, it was noted a better ejection fraction on the postoperative Echocardiography. Otherwise, no other differences ware noted in comparison with placebo.
The study is well conducted and the manuscript well written and the limitation well described.
Reviewer 2 Report
Intraoperative hyperglycemia is an independent risk factor for complications, including death, after cardiac surgery. Sofar insulin was the only therapeutic option. Since GLP1 has a direct effect on the heart, GLP1 receptor agonist effect on myocardial functions is an important investigation. The manuscript was organized well with a clear description. As authors have stated further studies required to validate the use and beneficial effects of the subcutaneous introduction of liraglutide during cardiac surgery.
